global genes

HNF Presents at RARE Patient Advocacy Summit Hosted by Global Genes®

by | Oct 1, 2018 | 0 comments

The Annual RARE Patient Advocacy Summit, hosted by Global Genes, is in its seventh year and will take place on October 3-4 at the Hotel Irvine in Irvine, California. It is the largest gathering of rare disease patients, advocates and thought leaders worldwide. Global Genes is one of the leading rare disease patient advocacy organizations in the world. There mission is to eliminate the challenges of Rare Diseases.

For the first time, HNF will be part of the agenda and has been asked to speak on two sessions: Architecting Your Disease Community, as well as Data and Technological Innovation. Allison Moore, HNF CEO and Joy Aldrich, HNF Advocacy Director will present “Update from the Community: Patient-Focused Drug Development Meetings” alongside Dr. Jill Jarecki, Chief Scientific Officer, Cure SMA. They will lead a discussion on the process, challenges and benefits of engaging in the effort to help understanding of the patients’ disease experience and that their treatment priorities are included in drug development and review.

Allison Moore will present the new proprietary GRIN platform and technological innovations that are revolutionizing the type of data that can be collected when capturing specific patient reported outcomes. By utilizing Voice Activation Technology (VAT), HNF can better capture in the patient’s voice PROs on pain and behavioral health. This type of data may enhance a better understanding of what patients are going through and a tool once validated to be incorporated into clinical trials.

Kent Thoelke, Executive Vice President and Chief Scientific Officer from PRA Health Sciences, a leading CRO company will present on the challenges in conducting research in the rare disease populations. He will emphasis the importance of the patient perspective on clinical research and leveraging data to guide clinical trial design and the utilization of technology to create patient-focused virtual clinical trials. These innovations provide a way not just to collect better data, but also to collect data that is truly patient-centric and may improve the future of drug development and clinical trials. #2018GGSummit

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news